14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CWAN vs BRZE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Clearwater Analytics Holdings, Inc. (CWAN) is the stronger overall head-to-head candidate over Braze, Inc. (BRZE) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CWAN carries a Unified Composite Score of 63.2/100 (BUY) at $24.56 (94.5x Forward P/E, 4.1% operating margin), whereas BRZE carries 35.6/100 (SELL) at $46.28 (72.8x Forward P/E, -11.9% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CWAN vs BRZE. Trailing 12-month operating profitability (CWAN 4.1% vs BRZE -11.9%) and valuation multiples (CWAN 94.5x vs BRZE 72.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Software - Application value chain with $5.3B market capitalization and -11.9% operating margin.
OpEx & R&D Reinvestment78.2% of Rev ($652M)
90D Engineering Disclosures0 Published
Investor FAQ CWAN vs BRZE Key Questions & Quantitative Answers
As of Nov 20, 2026, Clearwater Analytics Holdings, Inc. (CWAN) is the stronger overall head-to-head candidate over Braze, Inc. (BRZE) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CWAN carries a Unified Composite Score of 63.2/100 (BUY) at $24.56 (94.5x Forward P/E, 4.1% operating margin), whereas BRZE carries 35.6/100 (SELL) at $46.28 (72.8x Forward P/E, -11.9% operating margin). Technically, CWAN sits in a Markup phase (RSI 67.9, UNCLASSIFIED options structure) and BRZE sits in a Markup phase (RSI 78.1, SURGE options structure).
CWAN leads the Growth & Scale pillar: CWAN posts +74.4% YoY revenue growth and +202.8% YoY earnings growth on $826M TTM revenue (66.0% gross margin, 4.1% operating margin), compared with BRZE at +26.2% YoY revenue growth and +0.0% YoY earnings growth on $834M TTM revenue (66.3% gross margin, -11.9% operating margin). On trailing 12-month operating scale, CWAN generates $826M in USD-normalized revenue versus $834M for BRZE. In operating R&D and SG&A reinvestment, CWAN deploys 61.9% of Rev ($511M) (0 90-day corporate R&D disclosures) versus 78.2% of Rev ($652M) (0 disclosures) for BRZE.
BRZE screens cheaper on headline valuation multiples. CWAN trades at 94.5x Forward P/E, 35.6x Trailing P/E, 1.78x PEG, and 8.9x EV/Revenue (13.2% EBITDA margin), whereas BRZE trades at 72.8x Forward P/E, 49.0x Trailing P/E, 1.63x PEG, and 6.2x EV/Revenue (9.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CWAN (-3.1% ROE) versus BRZE (-18.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CWAN carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.42β · 4% Vol realized risk). By comparison, BRZE carries 7.6% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.56β · 5% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.